Author:
Najafzadeh Mehdi,Schneeweiss Sebastian,Choudhry Niteesh,Bykov Katsiaryna,Kahler Kristijan H.,Martin Diane P.,Gagne Joshua J.
Subject
Public Health, Environmental and Occupational Health,Health Policy
Reference29 articles.
1. The future of drug safety—promoting and protecting the health of the public: FDA’s response to the Institute of Medicine’s 2006 report. 2007. Available from: http://www.fda.gov/downloads/drugs/drugsafety/postmarketdrugsafetyinformationforpatientsandproviders/ucm171627.pdf. [Accessed October 7, 2014].
2. Assessing a structured, quantitative health outcomes approach to drug risk-benefit analysis;Garrison;Health Aff (Millwood),2007
3. A review of quantitative risk-benefit methodologies for assessing drug safety and efficacy—report of the ISPOR Risk-Benefit Management Working Group;Guo;Value Health,2010
4. A framework for organizing and selecting quantitative approaches for benefit-harm assessment;Puhan;BMC Med Res Methodol,2012
5. Food and Drug Administration. FDA working with patients to explore benefit/risk: opportunities & challenges. Available from: http://www.fda.gov/ForConsumers/ByAudience/ForPatientAdvocates/ucm298136.htm. 2012. [Accessed October 7, 2014].
Cited by
17 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献